Iodixanol
Chemical compound
- V08AB09 (WHO)
- US: WARNING[1]Rx-only
- 5-{N-[3-(N-{3,5-bis[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}acetamido)-2-hydroxypropyl]acetamido}-1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
- 92339-11-2
Y
- 3724
- DB01249 Y
- 3593 Y
- HW8W27HTXX
- D01474 Y
- CHEBI:31705 Y
- ChEMBL1200507
N
- DTXSID2045523
- Interactive image
- Ic1c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c(I)c1N(C(=O)C)CC(O)CN(C(=O)C)c2c(I)c(c(I)c(c2I)C(=O)NCC(O)CO)C(=O)NCC(O)CO
- InChI=1S/C35H44I6N6O15/c1-13(52)46(30-26(38)20(32(59)42-3-15(54)9-48)24(36)21(27(30)39)33(60)43-4-16(55)10-49)7-19(58)8-47(14(2)53)31-28(40)22(34(61)44-5-17(56)11-50)25(37)23(29(31)41)35(62)45-6-18(57)12-51/h15-19,48-51,54-58H,3-12H2,1-2H3,(H,42,59)(H,43,60)(H,44,61)(H,45,62)Y
- Key:NBQNWMBBSKPBAY-UHFFFAOYSA-NY
N
Y (what is this?) (verify)Iodixanol, sold under the brand name Visipaque, is an iodine-containing non-ionic radiocontrast agent.[2]
It is available as a generic medication.[3][4]
Medical uses
The radiocontrast agent is given intravenously for computed tomography (CT) imaging of the head, body, excretory urography and venography. The radiocontrast agent is also given intra-arterially for angiography imaging.[5]
Adverse effects
About 30% of those received intravenous iodixanol injection has warmth, pain, or discomfort at the site of the injection. Other adverse effects include: taste perversion (3.5%), nausea (2.8%), and headache (2.5%).[5]
Society and culture
Available forms
The contrast can either be given intra-arterialy or intravenously.[5]
Veterinary uses
Iodixanol is also the active ingredient in a number of 'cushion' products used during the centrifugation of stallion semen. It is layered underneath the extended stallion semen allowing for a higher g force to be used with less sperm damage and better recovery rates. Post centrifugation the supernatant above and the cushion below is removed, leaving a concentrated sperm pellet in the conical tube.[6]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ Spencer CM, Goa KL (December 1996). "Iodixanol. A review of its pharmacodynamic and pharmacokinetic properties and diagnostic use as an x-ray contrast medium". Drugs. 52 (6): 899–927. doi:10.2165/00003495-199652060-00013. PMID 8957160. S2CID 195690679.
- ^ "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
- ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
- ^ a b c "Visipaque (iodixanol injection)" (PDF). US Food and Drug Administration. 1 September 2008. Archived from the original (PDF) on 8 April 2022.
- ^ Waite JA, Love CC, Brinsko SP, Teague SR, Salazar JL, Mancill SS, Varner DD (September 2008). "Factors impacting equine sperm recovery rate and quality following cushioned centrifugation". Theriogenology. 70 (4): 704–14. doi:10.1016/j.theriogenology.2008.04.047. PMID 18573520.
External links
- https://web.archive.org/web/20160825063320/http://www.cosmobiousa.com/axis-shield-density-gradient-optiprep.html
- http://www3.gehealthcare.com/en/products/categories/contrast_media/visipaque
- https://web.archive.org/web/20110927141156/http://www.gehealthcare.com/caen/md/docs/visipaquepieng.pdf
- Iodixanol drug label/data at DailyMed from U.S. National Library of Medicine, National Institutes of Health.
- v
- t
- e
| Iodinated, Water soluble |
| ||||||
|---|---|---|---|---|---|---|---|
| Iodinated, Water insoluble |
| ||||||
| Non-iodinated |
| Paramagnetic | |
|---|---|
| Superparamagnetic |
|
| Other |
- Microspheres of human albumin
- Microparticles of galactose
- Perflenapent
- Microspheres of phospholipids
- Sulfur hexafluoride
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
